"Vitamin D" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
| Descriptor ID |
D014807
|
| MeSH Number(s) |
D04.210.500.812.768
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vitamin D".
Below are MeSH descriptors whose meaning is more specific than "Vitamin D".
This graph shows the total number of publications written about "Vitamin D" by people in this website by year, and whether "Vitamin D" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 3 | 1 | 4 |
| 2007 | 3 | 4 | 7 |
| 2008 | 4 | 2 | 6 |
| 2009 | 2 | 3 | 5 |
| 2010 | 7 | 2 | 9 |
| 2011 | 3 | 4 | 7 |
| 2012 | 6 | 2 | 8 |
| 2013 | 8 | 4 | 12 |
| 2014 | 5 | 4 | 9 |
| 2015 | 13 | 3 | 16 |
| 2016 | 8 | 3 | 11 |
| 2017 | 8 | 2 | 10 |
| 2018 | 4 | 5 | 9 |
| 2019 | 5 | 3 | 8 |
| 2020 | 5 | 6 | 11 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 3 | 5 |
| 2025 | 2 | 1 | 3 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vitamin D" by people in Profiles.
-
Effect of moderate or high versus low dose daily vitamin D on COVID-19 incidence: A double-blind, parallel-group randomized clinical trial. Clin Nutr. 2026 Sep; 64:106722.
-
Vitamin D and Uterine Fibroids: Insights into Pathophysiology and Therapeutic Potential. Endocr Rev. 2026 May 13; 47(3):329-350.
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
-
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
-
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
-
Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. Am J Nephrol. 2026; 57(4):504-513.
-
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 08; 28(8):669-687.
-
Serum parathormone, vitamin D and cardiovascular risk factors and markers: A pilot study. Nutr Metab Cardiovasc Dis. 2024 10; 34(10):2298-2304.
-
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 06; 41(6):2500-2518.
-
Forgetting the Frail: National Trends in Vitamin D Prescription After Fragility Fracture-A Large Insurance Claims Database Study. J Am Acad Orthop Surg. 2024 May 15; 32(10):464-471.